Manufacturing and characterization of vaccines and other biologics
Ended Awarded Last action
- Contract number
- HHSN27200018
- Awardee
-
Advanced Bioscience Laboratories, Inc. UEI MK4QC9EKZXG8
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,745,188
Award facts
- Contract value 100% obligated
- $2,745,187.57 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541711 Research and Development in Biotechnology
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Rockville, MD 20850, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $48,822 | |
| Exercise an Option | $143,827 | |
| Exercise an Option | $283,502 | |
| Exercise an Option | $515,405 | |
| Exercise an Option | $350,000 | |
| Exercise an Option | $515,405 | |
| Exercise an Option | $379,737 | |
| Original award | $508,490 |
About this award
The federal contract award is to Advanced Bioscience Laboratories, Inc. (ABL), a foreign-owned, for-profit organization that specializes in the development of gene therapies, vaccines, oncolytics, and immunotherapies. The contract, with a ceiling value of $2,745,187.57, was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS). The contract is a Delivery Order with a Cost Plus Fixed Fee pricing type and does not have a set-aside designation.
ABL has been awarded numerous federal contracts and grants, particularly from NIH and HHS, to advance the development of medical countermeasures for various infectious diseases and other health conditions. Under this specific contract, ABL will likely provide a range of services to support preclinical and clinical development programs, including cGMP manufacturing of vaccines and biologics, process development, analytical testing, stability studies, and project management. The contract is part of ABL's broader portfolio of Indefinite Delivery Vehicles (IDVs) with federal agencies, demonstrating its comprehensive capabilities in supporting the development of vaccines, therapeutics, and diagnostics across multiple disease areas and federal health agencies.
Quick answers
Who was awarded contract HHSN27200018?
HHSN27200018 was awarded to Advanced Bioscience Laboratories, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on July 15, 2015.
How much is contract HHSN27200018 worth?
The government has obligated $2,745,188 on HHSN27200018.
Is contract HHSN27200018 an order under another contract?
Yes. HHSN27200018 is a delivery order under HHSN272201200005I, an indefinite delivery contract.
Was contract HHSN27200018 competed?
The extent of competition for HHSN27200018 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award